Physician profile
Harsh Shah
NPI 1790962116
$183,164.43
in general payments reported to CMS, 2019-2025
15 companies · $92K in 2025
The $92K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.04 · 2020: $76.67 · 2021: $134 · 2022: $7,818 · 2023: $16K · 2024: $67K · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $102K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Travel and Lodging: $7,323 · Food and Beverage: $6,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $102,490.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,000.00 |
| Travel and Lodging | $7,322.99 |
| Food and Beverage | $6,299.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $182,703.49 | 2022-2025 | Da Vinci Sp |
| Grifols USA, LLC | $59.77 | 2020-2022 | |
| Glaxosmithkline, LLC. | $59.31 | 2020-2023 | Trelegy Ellipta |
| Pulmonx Corporation | $54.09 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Actelion Pharmaceuticals US, INC. | $48.85 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $36.66 | 2019-2024 | Xarelto |
| Amgen INC. | $32.09 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $31.27 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $29.74 | 2021-2022 | |
| Philips North America LLC | $25.80 | 2021 | |
| Olympus America INC. | $24.33 | 2022 | |
| Mylan Specialty L.P. | $16.26 | 2021 | |
| Boston Scientific Corporation | $15.22 | 2020 | |
| Mallinckrodt Hospital Products INC. | $13.93 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harsh Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.